Our previous study demonstrated the anti-tumor efficacy of A20 CAR4 T cells targeting integrin αvβ6 [17] and the PD-1 and PD-L1 interaction can diminish the efficacy of CAR T cell therapy [22, 23]. Here, CD274 is linked to neoplasm.